Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors. Beqvez was approved in the U.S. last year, for the ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

Researchers have identified a gene therapy that could prevent life-threatening arrhythmias by restoring the heart’s ...

Cardiac arrhythmias affect millions across the world and are responsible for a fifth of all deaths in the Netherlands.

BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy that could potentially address unmet needs by inserting a functional copy of the CFTR gene in the DNA of airway epithelial ...

Researchers have suggested that uniform evidence standards and reporting requirements could help speed patient access to cell and gene therapies and help ensure consistent safety and efficacy ...

Recent innovations in DNA-modifying will revolutionize the treatment of many diseases and prompt crucial discussions.

A health district epidemiologist called it a “kick in the teeth” and based on “based on conspiracy and misinformation.” ...

The Philadelphia market has gained recognition not only for its cell and gene therapy sector but also its real estate scene and talent pool. Vittoria Biotherapeutics, Interius BioTherapeutics and ...